The session was dedicated to considering how patient engagement is being considered as part of medicinal product development, approval, and post-approval phases. Involving patients in the regulatory decision-making process is advancing and progress has been made in evolving frameworks over the last few years. Four short presentations set the scene for discussion, with contributions from regulators, patient representatives and healthcare providers.